Kodiak Sciences Q1 net loss $57.5M ($1.09/shr), cash $138.9M; pipeline on track for 2026 data

Kodiak Sciences Inc.

2025-Q1 EPS reported -$1.09

Net loss $57.5M ($1.09/shr) vs $43.0M ($0.82) in Q1 2024; non-cash stock comp $15.9M.
Cash and cash equivalents $138.9M; company believes current cash funds operations into 2026.
R&D expenses $43.6M, up from $29.9M YoY, driven by increased clinical and manufacturing activities.
Phase 3 GLOW2 (DR), DAYBREAK (wet AMD) for tarcocimab and KSI-501; Phase 1b APEX data for KSI-101 expected.
Investor R&D Update scheduled for July 16, 2025; topline data targeted in 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.